{"created":"2021-03-01T06:19:54.600401+00:00","id":15401,"links":{},"metadata":{"_buckets":{"deposit":"35b0d608-a6b4-47d7-acbd-15efcaac7f43"},"_deposit":{"id":"15401","owners":[],"pid":{"revision_id":0,"type":"depid","value":"15401"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00015401","sets":["453:456","471:537:538:1086"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Rationale, Guidelines and Goals of Treatment of Hypertension in Community Medicine : From Standpoint of Coronary Heart Disease Prevention"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2000-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"216","bibliographicPageStart":"211","bibliographicVolumeNumber":"114","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"According to epidemiologic and large-scale therapeutic trials, the risk of cardiovascular morbidity and mortality rises progressively with increasing blood pressure (BP) levels. Although both of systolic BP and diastolic BP are significant predictors of death due to coronary heart disease (CHD) in all aged groups, systolic BP is a stronger predictor than diastolic BP. Ambulatory systolic BP is a more useful tool for the prediction of subsequent cardiovascular event than conventional BP. The meta-analysis of major prospective observational studies demonstrates that for the large majority of individuals, a lower BP should eventually confer a lower risk of vascular disease. From standpoint of CHD prevention, the evidence of the effectiveness of antihypertensive treatment in the elderly is stronger than in younger and middle-aged subjects. In younger and middle-aged subjects, if a cluster of multiple risk factors is present, the hazard is formidable. Evaluation of hypertensives as a candidate for CHD must include at a minimum a blood lipid profile, a blood sugar determination, an ECG for LVH and a history of cigarette smoking. The JNC VI gives attention to the overall risk status as well as the levels of BP in deciding on the need for drug therapy and also recommends that the subjects with major risk factor, target organ damage, or clinical cardiovascular disease should be pharmacologically treated even if the BP is high normal levels.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"98722","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Igarashi, Yutaka"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"五十嵐, 裕"}],"nameIdentifiers":[{"nameIdentifier":"98721","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-07"}],"displaytype":"detail","filename":"114(6)_211-216.pdf","filesize":[{"value":"996.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"114(6)_211-216.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/15401/files/114(6)_211-216.pdf"},"version_id":"06e5ef85-a5bc-4435-bbb0-cd3095ebc7bb"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"hypertension","subitem_subject_scheme":"Other"},{"subitem_subject":"Coronary Heart Disease","subitem_subject_scheme":"Other"},{"subitem_subject":"Drug therapy","subitem_subject_scheme":"Other"},{"subitem_subject":"高血圧症","subitem_subject_scheme":"Other"},{"subitem_subject":"虚血性心疾患","subitem_subject_scheme":"Other"},{"subitem_subject":"薬物療法","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"1)地域社会における高血圧症の位置づけ : 虚血性心疾患との関連（シンポジウム 高血圧治療の進歩, 第556回新潟医学会）","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"1)地域社会における高血圧症の位置づけ : 虚血性心疾患との関連（シンポジウム 高血圧治療の進歩, 第556回新潟医学会）"},{"subitem_title":"1)地域社会における高血圧症の位置づけ : 虚血性心疾患との関連（シンポジウム 高血圧治療の進歩, 第556回新潟医学会）","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1086"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-11-20"},"publish_date":"2017-11-20","publish_status":"0","recid":"15401","relation_version_is_last":true,"title":["1)地域社会における高血圧症の位置づけ : 虚血性心疾患との関連（シンポジウム 高血圧治療の進歩, 第556回新潟医学会）"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:47:09.452420+00:00"}